NeoTract Welcomes UK Government Announcement to Remove Barriers to Adoption of the UroLift® System for BPH Care for Every NHS Hospital in England

24.10.2018 07:00 | Business Wire

Del

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX)
focused on addressing unmet needs in the field of urology, today
welcomed the announcement that the company’s novel UroLift®
System for patients with Benign Prostatic Hyperplasia (BPH) has been
acknowledged by the UK Government as one of only seven Accelerated
Access Collaborative “Rapid Uptake Products.”

The UroLift System will now benefit from support from the Accelerated
Access Collaborative to rapidly increase its uptake in the NHS. This
enables transformative products to reach patients as quickly as possible
through streamlined regulatory and market access decisions.

Neil Barber, Consultant Urologist, Frimley Health NHS Foundation Trust,
was the first surgeon to routinely offer the UroLift System on the NHS.
Mr. Barber said, “I am very pleased by this news. Having been involved
in the initial European randomized clinical trial, the potential
benefits of the UroLift System to both patients and the NHS quickly
became very clear. What was evident from the beginning was that this is
an effective day case procedure that, for the first time, preserves
sexual function; we could offer most patients the likely prospect going
home catheter-free; and they would experience a rapid improvement in
symptoms and a return to normal activity with days rather than weeks as
is the case for more standard surgical options.

“What we have learned in the NHS setting since the first procedures in
2014 is that the UroLift System has hugely helped us to improve the use
of our resources. In my own Trust, we have been able to relocate the
site of operation from the classical operating theatre to a procedure or
minor ops room, and we are able to perform up to six UroLift System
procedures on one list. This helps us to release precious capacity and
reduce waiting times in other parts of our service.”

Teleflex Interventional Urology EMEA Vice President and General Manager,
Justin Hall, said: “We are humbled and honored to hear that the UroLift
System is one of the seven products that
Accelerated Access Collaborative has chosen to support, enabling rapid
increase in their uptake.

The inclusion of the UroLift System into the Accelerated Access
Collaborative Rapid Uptake Products list follows the decision by NHS
England in 2017 to name the treatment as one of the first recipients of
the first Innovation and Technology Tariff, which essentially helped to
fast track this minimally invasive, day case treatment into the NHS.

Mr. Hall added, “Today’s announcement shows that the Government
acknowledges the treatment’s unique clinical benefits and our quality of
robust clinical evidence, and increasingly, real world data, gathered
from NHS urologists. Their experience shows that using the UroLift
System allows them to deliver benefits for NHS urology departments: in
terms of reducing overall costs and complications; saving substantial
numbers of bed days; and hours of operating theatre time. The UroLift
System potentially frees capacity for urologists to focus on critical
cancer targets and waiting times, reducing delays in urgent and planned
surgery.

“Our close partnership with NHS clinicians and regulators is enabling a
true service transformation: not only for men and their treatment
options but also in terms of developing a methodology of how to adopt a
disruptive healthcare technology, such as The UroLift System, and embed
it into the NHS, in a comparatively markedly shorter time than previous
innovations.”

Jean-Luc Dianda, President, EMEA,Teleflex, said, “The UroLift System is
a recent acquisition for Teleflex, and we believe it perfectly fits our
mission statement to deliver medical technologies designed to improve
the health and quality of people’s lives. Today’s announcement
demonstrates that the treatment is now also additionally acknowledged as
a transformative technology within a major public healthcare system.”

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive
technology for treating lower urinary tract symptoms due to benign
prostatic hyperplasia (BPH). The UroLift permanent implants, delivered
during a minimally invasive transurethral outpatient procedure, relieve
prostate obstruction and open the urethra directly without cutting,
heating, or removing prostate tissue. Clinical data from a pivotal
206-patient randomized controlled study showed that patients with
enlarged prostate receiving UroLift implants reported rapid and durable
symptomatic and urinary flow rate improvement without compromising
sexual function. Patients also experienced a significant improvement in
quality of life. Nearly 70,000 men have been treated with the UroLift
System in the U.S. Most common adverse events reported include
hematuria, dysuria, micturition urgency, pelvic pain, and urge
incontinence. Most symptoms were mild to moderate in severity and
resolved within two to four weeks after the procedure. The UroLift
System Prostatic Urethral Lift procedure is recommended for the
treatment of BPH in both the American Urological Association and
European Association of Urology clinical guidelines. The UroLift System
is available in the U.S., Europe, Australia, Canada, Mexico and South
Korea. Learn more at www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the NeoTract
Interventional Urology Business Unit is dedicated to developing
innovative, minimally invasive and clinically effective devices that
address unmet needs in the field of urology. Our initial focus is on
improving the standard of care for patients with BPH using the UroLift
System, a minimally invasive permanent implant system that treats
symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to
improve the health and quality of people’s lives. We apply purpose
driven innovation – a relentless pursuit of identifying unmet clinical
needs – to benefit patients and healthcare providers. Our portfolio is
diverse, with solutions in the fields of vascular and interventional
access, surgical, anesthesia, cardiac care, urology, emergency medicine
and respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For more
information, please visit www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®,
Rusch®, UroLift® System and Weck® – trusted brands united by a common
sense of purpose.